Skip to content

Orphan Drug BioTech Stock Predictions For 2013: Perspective

January 2, 2013

       Adam Feuerstein from predicts BioTech stock activity for 2013. The following are the orphan drug predictions from his list for 2013 :

1) 2013 will be a great year for Sarepta Therapeutics :

– Accelerated approval filing mid-2013 for Eteplirsen in the US for the treatment of Duchenne Muscular Dystrophy (DMD)

– Ex-US partnership for exon-skipping drug technology platform.

2) “Orphan drug pricing comes under scrutiny & increasing criticism”

3) Following orphan drug companies to be involved in M&A deals :

– BioMarin Pharmaceuticals

– Onyx Pharmaceuticals

– Incyte Corporation.

4) Cell Therapeutics raises money twice

5) Celgene to be the “best-performing large-cap biotech in 2013”

6) Strong orphan drug launches :

– NPS Pharmaceuticals’ Gattex (Teduglutide) for Short Bowel Syndrome (SBS)

– Aegerion Pharmaceuticals’ Juxtapid (Lomitapide) for Homozygous Familial Hypercholesterolemia (HoFH)

– Onyx Pharmaceuticals’ Kyprolis (Carfilzomib) for Multiple Myeloma.

7) Weak orphan drug launches :

– Ariad Pharmaceuticals’ Iclusig (Ponatinib) for Chronic Myeloid Leukemia (CML)

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: